Lineage Cell Therapeutics... (LCTX)
AMEX: LCTX
· Real-Time Price · USD
1.01
-0.01 (-0.98%)
At close: Jul 03, 2025, 3:34 PM
1.02
0.99%
After-hours: Jul 03, 2025, 04:51 PM EDT
-0.98% (1D)
| Bid | 1.01 |
| Market Cap | 230.64M |
| Revenue (ttm) | 9.56M |
| Net Income (ttm) | -16.21M |
| EPS (ttm) | -0.07 |
| PE Ratio (ttm) | -14.43 |
| Forward PE | -20.2 |
| Analyst | Buy |
| Ask | 1.05 |
| Volume | 912,561 |
| Avg. Volume (20D) | 2,208,268 |
| Open | 1.04 |
| Previous Close | 1.02 |
| Day's Range | 0.99 - 1.06 |
| 52-Week Range | 0.37 - 1.15 |
| Beta | 1.52 |
About LCTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LCTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LCTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
-28.99%
Lineage Cell Therapeutics shares are trading lower...
Unlock content with
Pro Subscription
11 months ago
+1.8%
Lineage Cell Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
3 weeks ago · https://www.defenseworld.net
Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)Squarepoint Ops LLC acquired a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) during the 4th quarter, according to the company in its most recent filing with the ...
1 month ago · seekingalpha.com
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call TranscriptLineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2025 - Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Offi...
